Cat allergy vaccine trial gets go-ahead to launch in UK

French-Canadian pharmaceutical firm Angany has announced that it has received clearance to initiate its first clinical trial investigating a vaccine intended to treat allergy to cats.

The company has confirmed that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has given it the go-ahead to launch the trial to evaluate its vaccine candidate ANG-101 at the Royal Brompton Hospital in London.